Sekai Biotech Established to Develop an AI-Powered Cell World Model
May 25, 2026
We are pleased to announce that Sekai Biotech, Inc. (headquartered in Tokyo; Representative Director: Takayoshi Kawakami) was established on May 25, 2026, to research, develop, and deploy the Cell World Model. The Cell World Model is an AI platform that tightly integrates automated experimentation, world models, and reinforcement learning to predict and control cellular states.
Background
In drug discovery and life science research, enormous experimentation and trial-and-error are required, and the development of new treatments takes a long time and considerable cost.
In recent years, the progress of generative AI and world models has greatly expanded the possibilities of AI in predicting and understanding the real world. On the other hand, in the field of life sciences, its potential has not been fully utilized due to challenges such as the complexity of biological data and integration with experimental systems.
Sekai Biotech aims to achieve a "Cellular World Model" that predicts and controls cellular state changes by building a unique AI platform that integrates automated experimental systems, reinforcement learning, and world models. Through closed-loop R&D that continuously cycles AI and experimentation, we are transforming the very nature of exploration in life sciences and working to accelerate and advance research and development.
Business activities
Our company promotes research and development in the following areas by leveraging cell world models.
- Development of a pathological assessment model
- Development of a toxicity assessment model
- Building an AI Platform for Drug Discovery Research
- Cell State Prediction and Control Technology Research and Development
In the future, we aim to provide new AI infrastructure that supports the decision-making of researchers and companies in the fields of drug discovery, regenerative medicine, and biotechnology.
Company Profile
Company / OrganizationSekai Biotech Co., Ltd.
EstablishedMay 25, 2026
RepresentativeRepresentative Director, Takayoshi Kawakami
Business activitiesDevelopment of Pathological and Toxicological Evaluation Models Utilizing Cell World Models